eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
3/2022
vol. 38
 
Share:
Share:
abstract:
Review paper

Vaccine-induced immune thrombotic thrombocytopaenia – overview

Jakub Sleziak
1
,
Antoni Gawor
1
,
Krzysztof Gomułka
2

  1. Student Research Group of Adult Allergology, Wroclaw Medical University, Wroclaw, Poland Head of the Group: Dr. Krzysztof Gomułka
  2. Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, Wroclaw, Poland Head of the Department: Dr. Robert Pawłowicz
Medical Studies/Studia Medyczne 2022; 39 (3): 226–232
Online publish date: 2022/09/30
View full text Get citation
 
PlumX metrics:
In response to the ongoing COVID-19 pandemic, pharmaceutical companies have been able to rapidly develop and distribute effective vaccines. Despite some common, minor, local, and systemic adverse effects following vaccination, there is also, in rare cases, a potential for the development of anti-platelet factor 4 antibodies, resulting in platelet activation and aggregation leading to potentially life-threatening thrombosis. Vaccine-induced immune thrombocytopaenia (VITT) is a rare immune response following administration of adenoviral vector vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) such as ChAdOx1 nCoV-19 AstraZeneca – Oxford and Ad26.COV2. S Johnson & Johnson. Since the discovery of the syndrome, the mortality rate has decreased by 90%. Therefore, in this paper, data including epidemiology and pathophysiology of the syndrome, followed by the diagnosis criteria and management options, were collected. The authors believe that spreading knowledge further among primary care physicians and other healthcare professionals will lead to better VITT treatment outcomes.
keywords:

COVID-19, thrombosis, thrombocytopaenia, vaccines, platelet factor 4

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.